Literature DB >> 8049830

Fibrosing alveolitis in systemic sclerosis. Bronchoalveolar lavage findings in relation to computed tomographic appearance.

A U Wells1, D M Hansell, M B Rubens, P Cullinan, P L Haslam, C M Black, R M Du Bois.   

Abstract

Fibrosing alveolitis in systemic sclerosis is histologically identical to lone cryptogenic fibrosing alveolitis (CFA) (idiopathic pulmonary fibrosis). The inflammatory cell content of bronchoalveolar lavage (BAL) samples has been used as a guide to prognosis and treatment in CFA. In this study, the relationship was explored between BAL findings and the extent and pattern of disease within the lavaged lobe, as judged by thin-section computed tomography (CT), in systemic sclerosis. Thirty-eight nonsmoking patients were studied; none had been treated with corticosteroids or immunosuppressive agents, and 11 had no evidence of fibrosing alveolitis on CT. BAL neutrophils were markedly increased in association with extensive disease on CT compared with less extensive disease (p < 0.001) and normal appearances (p < 0.001); the extent of a reticular pattern on CT (denoting fibrosis) correlated with the neutrophil percentage count (p < 0.005) and total neutrophil count/ml (p < 0.01). BAL eosinophils were increased in less extensive as well as in extensive disease when compared with lobes with a normal CT appearance (p < 0.01); eosinophil percentage counts but not total eosinophil counts/ml correlated with the extent of a ground-glass pattern on CT (through to denote inflammation) (p < 0.05). These findings indicate that in systemic sclerosis a BAL neutrophilia is generally associated with extensive fibrotic disease, whereas a BAL eosinophilia is often seen in less advanced disease, particularly when CT appearances suggest lung inflammation.

Entities:  

Mesh:

Year:  1994        PMID: 8049830     DOI: 10.1164/ajrccm.150.2.8049830

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  21 in total

Review 1.  Clinical usefulness of high resolution computed tomography in cryptogenic fibrosing alveolitis.

Authors:  A Wells
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

Review 2.  The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Introduction.

Authors: 
Journal:  Thorax       Date:  1999-04       Impact factor: 9.139

Review 3.  Lung involvement in systemic sclerosis.

Authors:  Paul M Hassoun
Journal:  Presse Med       Date:  2010-12-30       Impact factor: 1.228

Review 4.  Interstitial lung disease in systemic sclerosis.

Authors:  O Kaloudi; I Miniati; S Alari; M Matucci-Cerinic
Journal:  Intern Emerg Med       Date:  2007-12-17       Impact factor: 3.397

5.  Bronchoalveolar lavage in systemic sclerosis with lung involvement: role and correlations with functional, radiological and scintigraphic parameters.

Authors:  Stefania Volpinari; Renato La Corte; Stefano Bighi; Franco Ravenna; Napoleone Prandini; Andrea Lo Monaco; Francesco Trotta
Journal:  Rheumatol Int       Date:  2010-03-30       Impact factor: 2.631

6.  Relationship between cells obtained by bronchoalveolar lavage and survival in idiopathic pulmonary fibrosis.

Authors:  K A Boomars; S S Wagenaar; P G Mulder; H van Velzen-Blad; J M van den Bosch
Journal:  Thorax       Date:  1995-10       Impact factor: 9.139

7.  Pulmonary involvement in diffuse cutaneous systemic sclerosis: broncheoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis.

Authors:  C Witt; A C Borges; M John; I Fietze; G Baumann; A Krause
Journal:  Ann Rheum Dis       Date:  1999-10       Impact factor: 19.103

8.  Correlation between HRCT findings, pulmonary function tests and bronchoalveolar lavage cytology in interstitial lung disease associated with rheumatoid arthritis.

Authors:  J Biederer; A Schnabel; C Muhle; W L Gross; M Heller; M Reuter
Journal:  Eur Radiol       Date:  2003-10-14       Impact factor: 5.315

Review 9.  Scleroderma lung: pathogenesis, evaluation and current therapy.

Authors:  Jacob M van Laar; Jan Stolk; Alan Tyndall
Journal:  Drugs       Date:  2007       Impact factor: 9.546

10.  Scleroderma lung disease.

Authors:  Jérôme Le Pavec; David Launay; Stephen C Mathai; Paul M Hassoun; Marc Humbert
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.